GC Corp. (KRX:005250)

Market Cap	468.09B -34.5%
Revenue (ttm)	2.49T +11.8%
Net Income	-88.86B
EPS	-1,979.69
Shares Out	45.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	300.00 (2.91%)
Ex-Dividend Date	Mar 30, 2026

Volume	79,798
Open	10,190
Previous Close	10,260
Day's Range	10,050 - 10,350
52-Week Range	8,630 - 18,010
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GC Corp.

GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1967
• Employees: 144
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 005250

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 7, 2026

Data Sources Report a data error